Key Points
- Director Michael Perry sold 16,250 shares at an average price of $61.03 for about $991,737.50, reducing his stake by 12.36% to 115,240 shares valued at roughly $7.03 million.
- ARWR opened at $68.83 and is trading near its 52‑week high of $71.50, with a market cap of $9.35 billion and a negative price‑to‑earnings ratio, highlighting biotech valuation volatility.
- Analysts hold a consensus rating of "Moderate Buy" with an average target of $55.44, reflecting a mix of recent upgrades and varied opinions (2 Strong Buy, 5 Buy, 3 Hold, 1 Sell).
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Michael Perry sold 16,250 shares of the firm's stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $61.03, for a total transaction of $991,737.50. Following the transaction, the director directly owned 115,240 shares of the company's stock, valued at $7,033,097.20. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Arrowhead Pharmaceuticals Price Performance
Shares of ARWR stock opened at $68.83 on Wednesday. The stock's fifty day simple moving average is $43.40 and its 200 day simple moving average is $28.40. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $71.50. The firm has a market cap of $9.35 billion, a price-to-earnings ratio of -860.27 and a beta of 1.28. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86.
Institutional Trading of Arrowhead Pharmaceuticals
A number of institutional investors have recently modified their holdings of ARWR. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter worth $29,000. Virtus Advisers LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth about $34,000. Salomon & Ludwin LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth about $34,000. Nisa Investment Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 1,308 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $52,000. 62.61% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on ARWR. Royal Bank Of Canada lifted their price objective on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an "outperform" rating in a research report on Wednesday, November 19th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, December 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley boosted their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 26th. Finally, Piper Sandler increased their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an "overweight" rating in a research note on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $55.44.
Get Our Latest Report on ARWR
About Arrowhead Pharmaceuticals
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
